Target：FSHR

Fields：cAMP signaling pathway;Neuroactive ligand-receptor interaction;Ovarian steroidogenesis

Gene Name：FSHR

Protein Name：Follicle-stimulating hormone receptor

Human Gene Id：2492

Human Swiss Prot No：P23945

Mouse Gene Id：14309

Mouse Swiss Prot No：P35378

Rat Gene Id：25449

Rat Swiss Prot No：P20395

Immunogen：The antiserum was produced against synthesized peptide derived from human FSHR. AA range:211-260

Specificity：FSHR Polyclonal Antibody detects endogenous levels of FSHR protein.

Formulation：Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source：Polyclonal, Rabbit,IgG

Dilution：IHC: 100-300.WB 1:500 - 1:2000. ELISA: 1:5000.. IF 1:50-200

Purification：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration：1 mg/ml

Storage Stability：-15°C to -25°C/1 year(Do not lower than -25°C)

Other Name：FSHR;LGR1;Follicle-stimulating hormone receptor;FSH-R;Follitropin receptor

Observed Band(KD)：70kD

Background： The protein encoded by this gene belongs to family 1 of G-protein coupled receptors. It is the receptor for follicle stimulating hormone and functions in gonad development. Mutations in this gene cause ovarian dysgenesis type 1, and also ovarian hyperstimulation syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2010],

Function：disease:Defects in FSHR are a cause of ovarian dysgenesis 1 (ODG1) [MIM:233300]; also known as premature ovarian failure or gonadal dysgenesis XX type or XX gonadal dysgenesis (XXGD) or hereditary hypergonadotropic ovarian failure or hypergonadotropic ovarian dysgenesis with normal karyotype. ODG1 is an autosomal recessive disease characterized by primary amenorrhea, variable development of secondary sex characteristics, and high serum levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH).,disease:Defects in FSHR are a cause of ovarian hyperstimulation syndrome (OHSS) [MIM:608115]. OHSS is a disorder which occurs either spontaneously or most often as an iatrogenic complication of ovarian stimulation treatments for in vitro fertilization. The clinical manifestations vary from abdominal distention and discomfort to potentially life-threatening, massive ovarian enlargeme

Subcellular Location：Cell membrane ; Multi-pass membrane protein .

Expression：Sertoli cells and ovarian granulosa cells.